All In Biotech

NDA 204820 · Hikma

Mitigare

Colchicine · Oral · Alkaloid

Last checked: Nov 20, 2026Latest source record: May 16, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2014

Sep 26, 2014

Approved uses

1

Original approval plus efficacy supplements

Registered trials

313

94 Phase 3, 51 recruiting

FAERS reports

26,779

21,677 serious, 3,275 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 16, 2026.

MITIGARE (colchicine) capsules are indicated for prophylaxis of gout flares in adults. Limitations of Use: The safety and effectiveness of MITIGARE for acute treatment of gout flares during prophylaxis has not been studied. MITIGARE is not an analgesic medication and should not be used to treat pain from other causes. • MITIGARE is an alkaloid indicated for prophylaxis of gout flares in adults ( 1 ). Limitations of Use : • The safety and effectiveness of MITIGARE for acute treatment of gout flares during prophylaxis has not been studied. • MITIGARE is not an analgesic medication and should not be used to treat pain from other causes.

Mechanism: Colchicine’s effectiveness as a treatment for gout has been postulated to be due to its ability to block neutrophil-mediated inflammatory responses induced by monosodium urate crystals in synovial fluid. Colchicine disrupts the polymerization of β-tubulin into microtubules, thereby preventing the activation, degranulation, and migration of neutrophils to sites of inflammation. Colchicine also interferes with the inflammasome complex found in neutrophils and monocytes that mediates interleukin-1β (IL-1β) activation.

Therapeutic areas: Kidney and urology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • MITIGARE · COLCHICINE 0.6MG · CAPSULE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Colchicine" as an intervention, any sponsor and status, largest first.

All 313 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea2,435
  • off label use2,269
  • drug ineffective2,067
  • nausea1,819
  • fatigue1,657
  • dyspnoea1,376
  • arthralgia1,366
  • acute kidney injury1,315
  • headache1,285
  • vomiting1,231
  • toxicity to various agents1,230
  • pain1,158

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004223
2005284
2006236
2007232
2008253
2009419
2010536
2011816
2012695
2013564
2014625
2015971
20161,289
20171,295
20181,609
20192,140
20202,171
20211,835
20221,988
20232,113
20242,240
20252,498
20261,746

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Mitigare (Colchicine)

2024 spending

$14.0M

Beneficiaries

16,231

44,946 claims

Per beneficiary

$864

$6.03 per unit

View as table
YearSpending
2020$13,048,275
2021$36,530,092
2022$37,238,471
2023$24,983,908
2024$14,022,307

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 768 on PubMed

Sponsor: Hikma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.